Daratumumab,Talquetamab,Teclistamab,Pomalidomide
Genmab,Janssen
['dara ', 'mmsm', ' emd ']
aa3/
conclusion:
-tal+dara showing impressive rr/pfs in rrmm
- high-risk cytogenetics was low in this study? no detailed information regarding emd - triple rrmm 60%, rr in those who were dara refractory (d2) 76%, while bcma exposure 76%
#mmsm #myeloma #medtwitter #asco23 
Associate Professor,Plasma Cell disorder program Director, Division of HMCT/University of Kansas Medical Center, no COI, #USMIRC Founder, #mmsm @KUMedCenter